Brain microprotein atlas identifies a link to immune-cell energy function

Researchers at the Salk Institute and collaborating institutions have mapped an overlooked class of small proteins in human brain tissue, opening additional avenues for investigating cognitive aging. The study, published September 14 in Nature Aging, also connects one of these molecules to energy production in microglia, the brain’s resident immune cells.

The immediate contribution is a research resource: a catalogue that lets scientists examine molecules missing from conventional protein references. Its accompanying laboratory experiments identify a biological function worth investigating, but do not establish a way to prevent Alzheimer’s disease or preserve cognition.

Finding proteins that standard maps miss

Microproteins are short chains of amino acids, the building blocks of proteins. Their small size makes them difficult to detect and characterize. Salk’s announcement explains that this has left gaps in scientists’ understanding of which proteins brain cells produce and how those molecules influence cellular behavior.

The researchers revisited existing brain data using computational tools, including the laboratory’s ShortStop system, alongside mass spectrometry, which detects protein fragments. Matching computational predictions with physical measurements strengthens the evidence that a candidate molecule is actually produced.

The paper’s discovery workflow examined protein data from 610 postmortem frontal-cortex samples. After technical outlier exclusions, 480 individuals remained for the proteomic analysis. The researchers identified 1,067 microproteins with strong spectral evidence that were absent from reviewed UniProtKB entries. These numbers describe different stages of the analysis, rather than separate clinical trials.

The tissue collections included people with and without Alzheimer’s disease. Comparing those samples can reveal disease-associated differences, although it cannot determine whether a difference preceded illness or resulted from it.

A small molecule with an energy-related role

One candidate, micro-MKKS63, contains 63 amino acids and is encoded at the MKKS genetic locus. Its abundance was lower in Alzheimer’s tissue.

Researchers then disrupted its coding sequence in two independently generated HMC3 human microglial cell lines. Compared with control cells, both showed reduced basal oxygen consumption, ATP-linked respiration and maximal respiration—laboratory measures of mitochondrial energy metabolism.

That experiment supports a functional role in this cell model. It does not show that restoring the molecule improves memory, changes Alzheimer’s pathology in a living organism or extends healthy life. Those are separate questions requiring additional experiments.

A resource others can interrogate

The accompanying public research repository makes the atlas more useful than a fixed list of discoveries. Investigators can search candidates, examine their sequences and spectral evidence, and compare Alzheimer’s-associated expression patterns. Filters distinguish reviewed from unreviewed entries and allow users to select evidence thresholds before exporting data.

The repository also provides analysis scripts and instructions for reproducing summary statistics. Some upstream human datasets require controlled access, an important distinction between making analytical tools public and making every underlying donor record freely downloadable.

This structure allows other groups to choose candidates for independent testing and evaluate how strongly each identification is supported. A catalogue entry is a starting point for that work, rather than evidence that every listed molecule has a disease-related function.

What this means for healthy-aging research

Salk describes the atlas as a framework that could eventually be extended to other brain regions and tissues. For healthspan research, its value lies in widening the set of biological questions scientists can ask about cellular resilience and neurodegeneration.

The practical clinical implications remain preliminary. Observations in donated tissue and experiments in cultured cells cannot establish a screening test or treatment benefit. The next meaningful advances will require connecting specific microproteins to disease mechanisms and demonstrating that changing their activity produces beneficial outcomes in more representative models.